Article de Périodique
Use of varenicline versus bupropion and risk of psychiatric adverse events (2013)
Auteur(s) :
PASTERNAK, B. ;
SVANSTROM, H. ;
HVIID, A.
Année
2013
Page(s) :
1336-1343
Langue(s) :
Anglais
Refs biblio. :
26
Domaine :
Tabac / Tobacco / e-cigarette
Discipline :
PSY (Psychopathologie / Psychopathology)
Thésaurus mots-clés
ABSTINENCE
;
BUPROPION
;
TABAC
;
VARENICLINE
;
EFFET SECONDAIRE
;
SANTE MENTALE
;
ETUDE PROSPECTIVE
;
COMPARAISON
;
EPIDEMIOLOGIE DESCRIPTIVE
;
PSYCHOPATHOLOGIE
Thésaurus géographique
DANEMARK
Résumé :
Aim: To investigate whether varenicline use was associated with increased risk of psychiatric adverse events, compared with bupropion, another drug used for smoking cessation.
Design, setting and participants: We conducted a registry-based cohort study in Denmark, 2007-10, comparing new users of varenicline and bupropion in unmatched and 1 : 1 propensity score-matched analyses.
Measurements: Using Cox regression, we estimated the hazard ratio (HR) of any psychiatric adverse event (emergency department visit or in-patient admission with a psychiatric diagnosis) within 30 days following treatment initiation. The unmatched and matched analyses correspond to conventional crude and fully adjusted analyses, respectively.
Findings: In unmatched analyses, there were 106 (0.18%) psychiatric adverse events among 59 790 varenicline users (rate 22 events per 1000 person-years), compared with 46 (0.26%) events among 17 936 bupropion users (rate 31 per 1000); the HR was 0.69 [95% confidence interval (CI): 0.49-0.98]. In propensity score-matched analyses, 39 (0.22%) events occurred among 17 935 varenicline users (rate 27 per 1000), compared with 46 (0.26%) events among 17 935 bupropion users (rate 31 per 1000); varenicline was not associated with increased risk of psychiatric adverse events (HR 0.85, 95% CI: 0.55-1.30). The overall rate of psychiatric adverse events was substantially higher among participants with a history of psychiatric disorder than in patients without such history; the risk associated with varenicline did not differ significantly by history of psychiatric disorder. Conclusions: In Denmark, the risk of psychiatric adverse events diagnosed during an emergency department visit or in-patient admission was not significantly higher with varenicline use compared with bupropion.
HIGHLIGHTS:
Compared with bupropion use, varenicline use does not significantly increase the risk of psychiatric adverse events such as psychotic symptoms, hostility, homicidal ideation, or suicide attempt.
Design, setting and participants: We conducted a registry-based cohort study in Denmark, 2007-10, comparing new users of varenicline and bupropion in unmatched and 1 : 1 propensity score-matched analyses.
Measurements: Using Cox regression, we estimated the hazard ratio (HR) of any psychiatric adverse event (emergency department visit or in-patient admission with a psychiatric diagnosis) within 30 days following treatment initiation. The unmatched and matched analyses correspond to conventional crude and fully adjusted analyses, respectively.
Findings: In unmatched analyses, there were 106 (0.18%) psychiatric adverse events among 59 790 varenicline users (rate 22 events per 1000 person-years), compared with 46 (0.26%) events among 17 936 bupropion users (rate 31 per 1000); the HR was 0.69 [95% confidence interval (CI): 0.49-0.98]. In propensity score-matched analyses, 39 (0.22%) events occurred among 17 935 varenicline users (rate 27 per 1000), compared with 46 (0.26%) events among 17 935 bupropion users (rate 31 per 1000); varenicline was not associated with increased risk of psychiatric adverse events (HR 0.85, 95% CI: 0.55-1.30). The overall rate of psychiatric adverse events was substantially higher among participants with a history of psychiatric disorder than in patients without such history; the risk associated with varenicline did not differ significantly by history of psychiatric disorder. Conclusions: In Denmark, the risk of psychiatric adverse events diagnosed during an emergency department visit or in-patient admission was not significantly higher with varenicline use compared with bupropion.
HIGHLIGHTS:
Compared with bupropion use, varenicline use does not significantly increase the risk of psychiatric adverse events such as psychotic symptoms, hostility, homicidal ideation, or suicide attempt.
Affiliation :
Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
Cote :
Abonnement
Historique